ClinVar Miner

Submissions for variant NM_000465.4(BARD1):c.1977A>G (p.Arg659=) (rs147215925)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 15
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000417370 SCV000149532 likely benign not specified 2017-11-24 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Ambry Genetics RCV000115623 SCV000172745 likely benign Hereditary cancer-predisposing syndrome 2018-07-03 criteria provided, single submitter clinical testing Synonymous alterations with insufficient evidence to classify as benign
Invitae RCV000200663 SCV000252705 benign Familial cancer of breast 2020-12-08 criteria provided, single submitter clinical testing
Color Health, Inc RCV000115623 SCV000537399 benign Hereditary cancer-predisposing syndrome 2020-11-30 criteria provided, single submitter clinical testing
University of Washington Department of Laboratory Medicine, University of Washington RCV000200663 SCV000611875 likely benign Familial cancer of breast 2018-03-28 criteria provided, single submitter research The BARD1 variant designated as NM_000465.3:c.1977A>G (p.Arg659=) is classified as likely benign. The variant is present in approximately 1 in every 170 individuals with European ancestry (exac.broadinstitute.org), which is more common than cancer risk variants. In one observed family, the allele did not travel with breast cancer in the family, providing additional evidence that the BARD1 p.Arg659= is benign. This variant has been classified as likely benign by other laboratories (ClinVar Variation ID: 127727). Bayesian analysis integrating all of this data (Tavtigian et al, 2018, PMID:29300386) gives a <1% probability of pathogenicity, which is consistent with a classification of likely benign. This variant is not predicted to alter BARD1 function or modify cancer risk. A modest (less than 2 fold) increase in cancer risk due to this variant cannot be entirely excluded. This reclassification analysis was performed in conjunction with the family studies project as part of the University of Washington Find My Variant Study.
Institute for Biomarker Research,Medical Diagnostic Laboratories, L.L.C. RCV000115623 SCV000679696 likely benign Hereditary cancer-predisposing syndrome 2017-07-12 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000417370 SCV000696765 likely benign not specified 2018-11-16 criteria provided, single submitter clinical testing Variant summary: BARD1 c.1977A>G alters a non-conserved nucleotide resulting in a synonymous change. 5/5 computational tools predict no significant impact on normal splicing; however ESEfinder predicts binding motif alterations for RNA splicing enhancers. Supporting the prediction of altered binding motifs, a functional study showed that this variant was associated with a transcript lacking exons 2-9 resulting in a very short open reading frame (p.Cys53_Trp635delinsfsX12) in addition to full-length transcript at a ratio of 3.8 (full-length to short; Ratajska_2012), which was not seen in controls. In a recent functional study examining the effect of variant at the cellular level, the authors observed a significant increase of telomere abnormalities (Pilyugin_2017). Pathogenic variants in BARD1 gene confer increased risk of breast and/or ovarian cancer. Monoallelic germline mutations in BARD1 are estimated to confer up to a 3 fold increased risk for breast cancer compared to the general population (PMID: 22264603). Given the unknown clinical effect of this occasional splicing abnormality, the importance of these in vitro studies is unclear. This variant was found in 572/ 279550 control chromosomes (including one homozygous occurrence) at a frequency of 0.002, which is more than 8 times greater than the maximal expected frequency of a pathogenic allele (0.00025) in this gene. Additionally, the observed variant frequency within Ashkenazi Jewish control individuals in the gnomAD database and publications is approximately 30.8 fold of the estimated maximal expected allele frequency for a pathogenic variant in BARD1 causing Hereditary Breast and Ovarian Cancer phenotype (0.00025), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Ashkenazi Jewish origin. c.1977A>G has been reported in the literature and in one poster from Ambry Genetics in individuals affected with Hereditary Breast and Ovarian Cancer (Ratajska_2012, Ratajska_2015, Pesaran_2013) with a combined OR of 2.76. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as likely benign.
Counsyl RCV000200663 SCV000785727 likely benign Familial cancer of breast 2017-11-09 criteria provided, single submitter clinical testing
PreventionGenetics,PreventionGenetics RCV000586474 SCV000806115 uncertain significance not provided 2016-11-07 criteria provided, single submitter clinical testing
Mendelics RCV000200663 SCV000837946 likely benign Familial cancer of breast 2018-07-02 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000200663 SCV000885059 likely benign Familial cancer of breast 2020-02-01 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000586474 SCV000888806 benign not provided 2018-04-12 criteria provided, single submitter clinical testing
CeGaT Praxis fuer Humangenetik Tuebingen RCV000586474 SCV001153287 uncertain significance not provided 2017-05-01 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000200663 SCV001298994 uncertain significance Familial cancer of breast 2017-04-27 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001357201 SCV001552590 likely benign Malignant tumor of breast no assertion criteria provided clinical testing The BARD1 p.Arg659= variant was identified in 50 of 25,074 proband chromosomes (frequency: 0.002) from individuals or families with basal cell carcinoma and hereditary breast and ovarian cancer and was present in 14 of 9414 control chromosomes (frequency: 0.001) from healthy individuals (Suszynska 2019, Cho 2018). The variant was identified in dbSNP (rs147215925) as “with other allele” and ClinVar (classified as likely benign by GeneDx, Ambry Genetics, Mendelics and 4 other submitters, benign by Invitae, Color and Quest Diagnostics and uncertain significance by Integrated Genetics and Prevention Genetics). The variant was identified in control databases in 576 of 282,800 chromosomes (1 homozygous) at a frequency of 0.002 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: Ashkenazi Jewish in 81 of 10,366 chromosomes (freq: 0.008), Other in 24 of 7216 chromosomes (freq: 0.003), European in 398 of 129,128 chromosomes (freq: 0.003), Finnish in 33 of 25,118 chromosomes (freq: 0.001), Latino in 30 of 35,438 chromosomes (freq: 0.0008), African in 9 of 24,968 chromosomes (freq: 0.0004), South Asian in 1 of 30,612 chromosomes (freq: 0.00003), while the variant was not observed in the East Asian population. The p.Arg659= variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. The variant occurs at a non-highly conserved nucleotide outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.